Journal
CANCER LETTERS
Volume 179, Issue 2, Pages 141-150Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/S0304-3835(01)00873-4
Keywords
melatonin; breast cancers; mt1 receptors; retinoic orphan receptor alpha
Categories
Funding
- NCI NIH HHS [CA74035, CA54142] Funding Source: Medline
Ask authors/readers for more resources
Two putative melatonin receptors have been described including the cell surface G-protein-linked receptors, mt1 and MT2, and the nuclear retinoic orphan receptor alpha (RORalpha). The mL1 receptor, but not the MT2 receptor, is expressed in human breast tumor cell lines, and melatonin-induced growth suppression can be mimicked by the mt1 and MT2 agonist, AMMTC, and blocked by the antagonist, CBPT. RORalpha receptors are also expressed in MCF-7 breast cancer cells and the putative RORalpha agonist CPG-52608 inhibits MCF-7 cell growth but with a very different dose-response than melatonin. Finally, melatonin and AMMTC, but not CPG-52608, can repress RORalpha transcriptional activity in MCF-7 cells. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available